ArteraAI Announces Research Agreement with CorePlus

Date:

Share post:

ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today a research agreement with CorePlus, a high complexity CLIA-certified clinical and anatomic pathology laboratory headquartered in Carolina, Puerto Rico. The collaboration aims to further validate The ArteraAI Prostate Test in the Hispanic population.

“We are committed to ensuring that our models are trained on datasets that properly represent diverse patient populations,” said Andre Esteva co-founder and CEO of ArteraAI. “Working with CorePlus allows us to enhance our diversity efforts, providing a unique opportunity to conduct comprehensive analytical validation of our models across diverse ethnic groups.”

Prostate cancer is the most commonly diagnosed cancer among Hispanic men in the U.S., comprising more than 1 in 5 of all new cancer diagnoses. Research also shows that 7.2% of Hispanic men who are diagnosed with prostate cancer die from their disease, making it the 4th leading cause of cancer death among this population. In fact, prostate cancer-specific mortality has been shown to be highest in Puerto Rican men, higher than even non-Hispanic blacks.

Also Read: Prime Large Language Models (LLMs)

“We are thrilled to collaborate with ArteraAI to further the advancement and reduction of inequities in prostate cancer diagnosis and treatment,” said Mariano de Socarraz, CEO of CorePlus. “This research agreement provides a strong step forward in increasing understanding of differences and reducing disparities in access to precision diagnostics creating more equitable and personalized care for prostate cancer patients.”

ArteraAI remains committed to incorporating diverse datasets in the training of its AI models, with CorePlus marking the latest endeavor. This collaborative effort extends the work of ArteraAI’s MMAI models, which were deliberately developed using cohorts comprising approximately 20% African Americans— a percentage that mirrors the 16% prevalence of prostate cancer in this specific patient population. The research alliance with CorePlus will provide ArteraAI access to an extensive database of Hispanic patients. CorePlus has applied a prostate-specific artificial intelligence algorithm on more than 10,000 men.

Check Out The New TalkDev Podcast. For more such updates follow us on Google News TalkDev News.

TalkDev Bureau
TalkDev Bureau
The TalkDev Bureau has five well-trained writers and journalists, well versed in B2B enterprise technology industry, and constantly in touch with industry leaders for the latest trends, opinions, and other inputs- to bring you the best and latest in the domain.
spot_img

Related articles

Nvidia Replaces GeForce Experience with Unified App in Latest Driver Update

Nvidia's latest driver update, Version 566.36, removes GeForce Experience and replaces it with the new Nvidia app. This...

Pixeltable Launches Open-Source AI Infrastructure with USD 5.5 Million Funding

Pixeltable has launched an open-source AI data infrastructure, securing USD 5.5 million in seed funding led by The...

SHIZA Launches Developer Suite: No-Code AI Solutions for Individuals and Enterprises

HIZA has launched its Developer Suite, designed to facilitate the integration of AI and Web3 technologies. This platform,...

Web Performance Optimization Best Practices

Web performance optimization is crucial as every millisecond matters, especially as users grow increasingly impatient with slow-loading sites. Optimizing...